FAQ

The MOST COMMON side effects: Constipation or diarrhea Nausea and/or vomiting Heartburn Decreased appetite Injection site reactions Other LESS COMMON side effects: Gallbladder issues Pancreatitis Severe dehydration (due to vomiting) Kidney injury (due to dehydration) Thyroid C-cell tumors (based on animal studies) Severe gastroparesis Hair loss All medications come with the possibility of side effects, but that does not mean that you will experience them. Note: If you experience severe, persistent, or sudden intense pain, seek medical care immediately or call 911.

Certain medications may be compounded by licensed pharmacies when commercially available products are not appropriate or accessible. Compounded medications are not FDA-approved but are prepared in accordance with applicable pharmacy regulations.

Weight loss medications are not right for everyone. The following will disqualify you from these medications: Type 1 Diabetes Pregnancy or actively trying to conceive Breastfeeding Active pancreatitis Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia Type 2

Indications for lower dose GLP-1 therapy, also known as microdosing, includes adults seeking support with appetite regulation, metabolic health, potential anti-inflammatory effects, or weight management, even if they do not meet traditional BMI thresholds for overweight or obesity. It may be appropriate for those with early insulin resistance, blood sugar variability, metabolic syndrome risk factors, or sensitivity to standard dosing.  This dosing regimen is considered off-label and is not included in FDA-approved labeling.

Semaglutide works on the GLP-1 receptor which helps reduce appetite, slow stomach emptying, and improve blood sugar control. Tirzepatide activates two receptors (GLP-1 and GIP), which can enhance appetite control and metabolic effects. Both medications are highly effective, but studies show tirzepatide tends to produce greater average weight loss. Neither medication is "better". The right option depends on factors like treatment goals, tolerance, and medical history. Some patients respond better to Semaglutide, while others see stronger results with Tirzepatide.

Ages 12 years and older for weight management medications. Wegovy is FDA for children and adolescents aged 12 and older Pediatric eligibility is based on BMI percentile BMI is > 95th percentile for age and sex Medication is being used for chronic weight management NOT cosmetic weight loss Required lifestyle intervention Reduced calorie diet Increased physical activity These medications are adjuncts, not stand alone therapy.